Martin A. Graham

Birinapant (TL32711), a Bivalent SMAC Mimetic, Targets TRAF2-Associated cIAPs, Abrogates TNF-Induced NF-κB Activation, and Is Active in Patient-Derived Xenograft Models

Christopher A. Benetatos, Yasuhiro Mitsuuchi, Jennifer M. Burns et al. · Molecular Cancer Therapeutics · 2014 · 173 citations

Chemoprevention Strategy, Apoptosis, Immunology +22

Birinapant, a Smac-Mimetic with Improved Tolerability for the Treatment of Solid Tumors and Hematological Malignancies

Stephen M. Condon, Yasuhiro Mitsuuchi, Yijun Deng et al. · Journal of Medicinal Chemistry · 2014 · 149 citations

Surgical Oncology, Solid Tumors, Apoptosis +20

In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration

Yvonne S. Lin, G. Lockwood, Martin A. Graham et al. · Pharmacogenetics · 2001 · 134 citations

A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma

Ravi K. Amaravadi, Russell J. Schilder, Lainie P. Martin et al. · Molecular Cancer Therapeutics · 2015 · 126 citations

Surgical Oncology, Smac-mimetic Birinapant, Immunology +17

Temporal and Spatial Evolution of Therapy-Induced Tumor Apoptosis Detected by Caspase-3–Selective Molecular Imaging

Quang-Dé Nguyen, Ioannis Lavdas, James Gubbins et al. · Clinical Cancer Research · 2013 · 55 citations